FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Pfreundschuh

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Michael Pfreundschuh
CHOP intensification: not yet state of the art.
Lorenz Thurner; Marina Zaks; Klaus-Dieter Preuss; Evi Regitz; Rainer Maria Bohle; Elena Csernok; Natalie Fadle; Wolfgang L Gross; Andrea Hasenfus; Maria Kemele; Philipp Klemm; Thierry Martin; Jean-Louis Pasquali; Michael Pfreundschuh
Progranulin antibodies in autoimmune diseases.
Heike Horn; Michael Hummel; Wolfram Klapper; Markus Loeffler; Peter Möller; German Ott; Michael Pfreundschuh; Andreas Rosenwald; Christopher Schmelter; Norbert Schmitz; Reiner Siebert; Harald Stein; Lorenz Trümper; Marita Ziepert; Thomas F E Barth; Claudia Becher; Heinz-Wolfram Bernd; Sergio B Cogliatti; Alfred C Feller; Martin-Leo Hansmann
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Pfreundschuh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael Pfreundschuh
CHOP intensification: not yet state of the art.
The lancet oncology 2013;14(6):445-7.
2013: Lorenz Thurner; Marina Zaks; Klaus-Dieter Preuss; Evi Regitz; Rainer Maria Bohle; Elena Csernok; Natalie Fadle; Wolfgang L Gross; Andrea Hasenfus; Maria Kemele; Philipp Klemm; Thierry Martin; Jean-Louis Pasquali; Michael Pfreundschuh
Progranulin antibodies in autoimmune diseases.
Journal of autoimmunity 2013;42():29-38.
2013: Heike Horn; Michael Hummel; Wolfram Klapper; Markus Loeffler; Peter Möller; German Ott; Michael Pfreundschuh; Andreas Rosenwald; Christopher Schmelter; Norbert Schmitz; Reiner Siebert; Harald Stein; Lorenz Trümper; Marita Ziepert; Thomas F E Barth; Claudia Becher; Heinz-Wolfram Bernd; Sergio B Cogliatti; Alfred C Feller; Martin-Leo Hansmann
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Blood 2013;121(12):2253-63.
2013: Itziar Salaverria; Carsten Schwaenen; Monika Szczepanowski; Lorenz Trümper; Swen Wessendorf; Thorsten Zenz; Norbert Arnold; Baudis Michael; Susanne Bens; Birgit Burkhardt; Africa García-Orad; Wolfram Klapper; Markus Kreuz; Jasmin Lisfeld; Idoia Martin-Guerrero; Ilske Oschlies; Michael Pfreundschuh; Reiner Siebert
High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.
Genes, chromosomes & cancer 2013;52(2):150-5.
2013: Rebecca Körner; Frank Lammert; Darius Madjidi; Cornelia S L Müller; Frank Neumann; Lennart Bergeler; Natalie Fadle; Stefan Gräber; Frank Grünhage; Michael Pfreundschuh; Klaus-Dieter Preuss; Thomas Vogt; Claudia Pföhler
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients.
PloS one 2013;8(3):e58087.
2013: Jasmin Teresa Ney; Michael Pfreundschuh; Erich Franz Solomayer; Rainer Maria Bohle; Stefan Graeber; Frank Gruenhage; Ingolf Juhasz-Boess; Gunter Assmann
Genetic polymorphism of the OPG gene associated with breast cancer.
BMC cancer 2013;13():40.
2012: Norbert Schmitz; Lorenz Truemper; Andreas Viardot; Marita Ziepert; Martin Bentz; Peter Borchmann; Gottfried Doelken; Gerhard Ehninger; Bertram Glaß; Mathias Haenel; Markus Loeffler; Maike Nickelsen; Norma Peter; Michael Pfreundschuh; Andreas Rosenwald; Christian Ruebe; Christian Schmidt
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
The lancet oncology 2012;13(12):1250-9.
2012: Boris Kubuschok; Niels Murawski; Michael Pfreundschuh; Martina Sester; Carsten Zwick; Rainer Breit; Barbara Gärtner; Frank Hartmann; Gerhard Held; Jochem König; Frank Neumann
Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Human gene therapy 2012;23(12):1224-36.
2012: Jochen Jung; Dieter Kohn; Marc Molinger; Michael Pfreundschuh; Martin Schreiber; Gunter Assmann
Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome.
Seminars in arthritis and rheumatism 2012;42(3):266-70.
2012: Michael Pfreundschuh
Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(28):3433-5.
2012: Pieter Sonneveld; Marian Stevens-Kroef; Bronno van der Holt; Helgi van der Velde; Marinus van Marwijk Kooy; Edo Vellenga; Katja C Weisel; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; Dirk Hose; Anna Jauch; Marie-Jose Kersten; Walter Lindemann; Henk M Lokhorst; Michael Pfreundschuh; Reinier Raymakers; Hans Salwender; M Ronald Schaafsma; Christof Scheid; Ingo G H Schmidt-Wolf; Uta Bertsch; Igor W Blau; Gerard M J Bos; Annemiek Broyl; Ulrich Duehrsen; Laila El Jarari; Hartmut M Goldschmidt
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(24):2946-55.
2012: Christina Heemann; Wolfram Jung; Markus Kreuz; Markus Loeffler; Michael Pfreundschuh; Nils Schoof; Irene Stoller; Lorenz Trümper; Frederike von Bonin; Marita Ziepert; Martin Hafner
Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(13):3637-47.
2012: Peter Dreger; Ulrich Dührsen; Anna-Maria Fink; Hildegard Greinix; Michael Hallek; Manfred Hensel; Wolfgang Knauf; Michael Kneba; Fabienne McClanahan; Michael Pfreundschuh; Matthias Ritgen; Johannes Schetelig; Norbert Schmitz; Michael Stadler; Stephan Stilgenbauer; Dirk Winkler; Günter Brittinger; Andreas Bühler; Raymonde Busch; Hartmut Döhner
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Blood 2012;119(21):4851-9.
2012: Carsten Zwick; Michael Pfreundschuh
Fourteen-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP-14): use it right or do not use it at all.
Leukemia & lymphoma 2012;53(5):758-9.
2012: Nicolas Mounier; Michael Pfreundschuh; Alessandro Rambaldi; Anna Sureda; G W van Imhoff; Sebastian Wittnebel; Michel Attal; Mats Brune; Carmen Canals; Eulogio Conde; Gordon Cook; Jan Cornelissen; Charles Crawley; Roberto Foa; Christian Gisselbrecht; Jian-Jian Luan; John Maertens
High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(5):788-93.
2012: Norbert Schmitz; L Truemper; M Wolf; S Zeynalova; E Cavallin-Stahl; Bertram Glaß; M Haenel; U Kaiser; M Loeffler; Michael Pfreundschuh
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(5):1267-73.
2012: Carsten Müller; Niels Murawski; Christina Nickenig; Norma Peter; Michael Pfreundschuh; Viola Poeschel; Tanja Rixecker; Michael Wenger; Martin H J Wiesen; Samira Zeynalova; Carsten Zwick; Gerhard Held; Eva Lengfelder; Bernd Metzner; Marcel Reiser
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Blood 2012;119(14):3276-84.
2012: Kristina Heyne; Judith Huwer; Jasmin Teresa Ney; Michael Pfreundschuh; Vincent Zimmer; Gunter Assmann
Different apoptotic responses of RA synoviocytes depending on different genotypes of the mdm2 SNP T309G.
Apoptosis : an international journal on programmed cell death 2012;17(4):424-7.
2012: Kai Neben; Norma Peter; Michael Pfreundschuh; Marc S Raab; Hans Salwender; Christof Scheid; Ingo G H Schmidt-Wolf; Pieter Sonneveld; Christian Teschendorf; Helgi van de Velde; Bronno van der Holt; Katja Weisel; Mathias Haenel; Thomas Hielscher; Anthony D Ho; Dirk Hose; Anna Jauch; Walter Lindemann; Henk M Lokhorst; Hans Martin; Uta Bertsch; Igor W Blau; Hans G Derigs; Ulrich Dührsen; Hartmut Goldschmidt
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood 2012;119(4):940-8.
2012: Michael Pfreundschuh
The genealogy of SEREX.
Cancer immunity 2012;12():7.
2012: P Simon; R Bergner; C Pfoehler; Michael Pfreundschuh; M Schreiber; G Assmann
Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet.
Clinical and experimental rheumatology 2012;30(1):45-50.
2011: Manfred Ahlgrimm; Markus Kreuz; Michael Pfreundschuh; Klaus-Dieter Preuss; Evi Regitz; Joerg Bittenbring
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
Blood 2011;118(17):4657-62.
2011: Michael Pfreundschuh; Viola Poeschel; Lois Shepherd; Ofer Shpilberg; Rolf Stahel; Marek Trneny; Lorenz Trümper; Jan Walewski; Pier Luigi Zinzani; Peter de Nully Brown; Devinder S Gill; Sandra Grass; Ulrich Jaeger; Evelyn Kuhnt; Stein Kvaloy; Markus Loeffler; Armando López-Guillermo; Noel Milpied; Niels Murawski; Anders Osterborg; Ruth Pettengell
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
The lancet oncology 2011;12(11):1013-22.
2011: Klaus-Dieter Preuss; Sybille Raudies; Evi Regitz; Karl-Herbert Schäfer; Manfred Ahlgrimm; Joerg Bittenbring; Natalie Fadle; Gerhard Held; Markus Klotz; Niels Murwaski; Frank Neumann; Michael Pfreundschuh; Sandra Grass
Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A.
Blood 2011;118(12):3340-6.
2011: Frank Neumann; Kubilay Ertan; Boris Kubuschok; Klaus-Dieter Preuss; Werner Schmidt; Claudia Schormann; Stefan Stevanovic; Michael Pfreundschuh
A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
Cancer immunology, immunotherapy : CII 2011;60(9):1333-46.
2011: Carsten Zwick; F Hartmann; E Lengfelder; Markus Loeffler; Christina Nickenig; N Peter; Michael Pfreundschuh; V Pöschel; M Reiser; G Schlimok; Norbert Schmitz; J Schubert; S Zeynalova
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1872-7.
2011: Sandra Grass; Henry Lynch; Jane Lynch; Klaus-Dieter Preuss; Evi Regitz; Stephan Thome; Lorenz Trümper; Dennis D Weisenburger; Vinetta Witt; Florian Zettl; Natalie Fadle; Michael Pfreundschuh
Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM.
Blood 2011;118(3):635-7.
2011: Gilles Salles; Birgitta Sander; Laurie H Sehn; Christoph Thorns; Wanling Xie; Maria Calaminici; Elias Campo; Mukesh Chhanabhai; Daphne de Jong; Randy D Gascoyne; Philippe Gaulard; Anton Hagenbeek; Sandra Horning; Wolfram Klapper; Abigail Lee; Andrew Lister; Thierry Molina; Michael Pfreundschuh; John Raemaekers; Andreas Rosenwald; Edie Weller
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
Blood 2011;117(26):7070-8.
2011: Bin Qu; Jens Rettig; Heiko Rieger; Eva C Schwarz; Christian Junker; Carsten Kummerow; Misty Marshall; Ulf Matti; Frank Neumann; Varsha Pattu; Michael Pfreundschuh; Ute Becherer; Shruthi S Bhat; Markus Hoth
Docking of lytic granules at the immunological synapse in human CTL requires Vti1b-dependent pairing with CD3 endosomes.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(12):6894-904.
2011: Gunter Assmann; Claudia Pfoehler; Pierre Simon; Michael Pfreundschuh; Wolfgang Tilgen; Stefan Wieczorek
Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study.
The Journal of dermatology 2011;38(6):519-23.
2011: Verena I Gaidzik; Lars Bullinger; Richard F Schlenk; Andreas S Zimmermann; Jürgen Röck; Peter Paschka; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Daniela Späth; Andrea Kündgen; Ingo G H Schmidt-Wolf; K Götze; David Nachbaur; Michael Pfreundschuh; Heinz A Horst; Hartmut Döhner; Konstanze Döhner
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(10):1364-72.
2011: Sandra Grass; Klaus-Dieter Preuss; Alexandra Wikowicz; Evangelos Terpos; Marita Ziepert; Diana Nikolaus; Yin Yang; Natalie Fadle; Evi Regitz; Meletios A Dimopoulos; Steven P Treon; Zachary R Hunter; Michael Pfreundschuh
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.
Blood 2011;117(10):2918-23.
2011: Sandra Grass; Shinsuke Iida; Aleksandra Wikowicz; Klaus-Dieter Preuss; Atsushi Inagaki; Kazuyuki Shimizu; Marita Ziepert; Ryuzo Ueda; Michael Pfreundschuh
Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma.
Cancer science 2011;102(3):565-8.
2011: M Rieger; A Osterborg; R Pettengell; D White; D Gill; J Walewski; E Kuhnt; Markus Loeffler; Michael Pfreundschuh; Anthony Ho
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):664-70.
2011: Lorenz Thurner; Antje Müller; Martine Cérutti; Thierry Martin; Jean-Louis Pasquali; Wolfgang L Gross; Klaus-Dieter Preuss; Michael Pfreundschuh; Jan Voswinkel
Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin.
Journal of autoimmunity 2011;36(1):87-90.
2011: Claudia E Rübe; Andreas Fricke; Thomas A Widmann; Tobias Fürst; Henning Madry; Michael Pfreundschuh; Christian Rübe
Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging.
PloS one 2011;6(3):e17487.
2010: Michael Pfreundschuh
How I treat elderly patients with diffuse large B-cell lymphoma.
Blood 2010;116(24):5103-10.
2010: German Ott; Marita Ziepert; Wolfram Klapper; Heike Horn; Monika Szczepanowski; Heinz-Wolfram Bernd; Christoph Thorns; Alfred C Feller; Dido Lenze; Michael Hummel; Harald Stein; Hans Konrad Müller-Hermelink; Matthias Frank; Martin-Leo Hansmann; Thomas F E Barth; Peter Möller; Sergio B Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Markus Loeffler; Andreas Rosenwald
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
Blood 2010;116(23):4916-25.
2010: Norbert Schmitz; Lorenz Trümper; Marita Ziepert; Maike Nickelsen; Anthony D Ho; Bernd Metzner; Norma Peter; Markus Loeffler; Andreas Rosenwald; Michael Pfreundschuh
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Blood 2010;116(18):3418-25.
2010: Niels Murawski; Michael Pfreundschuh
New drugs for aggressive B-cell and T-cell lymphomas.
The lancet oncology 2010;11(11):1074-85.
2010: Adnan Alahmad; Klaus-Dieter Preuss; Joachim Schenk; Wolfgang Füreder; Hubert Schrezenmeier; Nikolaus Müller-Lantzsch; Jörg Schubert; Michael Pfreundschuh
Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 2010;151(3):273-80.
2010: Bertram Glaß; M Ziepert; M Reiser; M Freund; L Trümper; B Metzner; A Feller; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2255-61.
2010: Michael Böhm; Ulrich Laufs; Michael Pfreundschuh
Angiotensin-receptor blockade, cancer, and concerns.
The lancet oncology 2010;11(9):818-9; author reply 821-2.
2010: Sanne Lugthart; Stefan Gröschel; Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3890-8.
2010: Franck Morschhauser; Françoise Kraeber-Bodéré; William A Wegener; Jean-Luc Harousseau; Marie-Odile Petillon; Damien Huglo; Lorenz H Trümper; Johannes Meller; Michael Pfreundschuh; Carl-Martin Kirsch; Ralph Naumann; Joachim Kropp; Heather Horne; Nick Teoh; Steven Le Gouill; Caroline Bodet-Milin; Jean-François Chatal; David M Goldenberg
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(23):3709-16.
2010: Gunter Assmann; Annette D Wagner; Mueller Monika; Claudia Pfoehler; Michael Pfreundschuh; Wolfgang Tilgen; Klaus Roemer
Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome.
Rheumatology international 2010;30(10):1273-6.
2010: Sandra Reichrath; Cornelia S L Müller; Beate Gleissner; Michael Pfreundschuh; Thomas Vogt; Jörg Reichrath
Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines.
The Journal of steroid biochemistry and molecular biology 2010;121(1-2):420-4.
2010: Marita Ziepert; Dirk Hasenclever; Evelyn Kuhnt; Bertram Glaß; Norbert Schmitz; Michael Pfreundschuh; Markus Loeffler
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2373-80.
2010: Gunter Assmann; Jochem Koenig; Michael Pfreundschuh; Joerg T Epplen; Joern Kekow; Klaus Roemer; Stefan Wieczorek
Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study.
The Journal of rheumatology 2010;37(5):900-4.
2010: Carsten Zwick; Niels Murawski; Michael Pfreundschuh
Rituximab in high-grade lymphoma.
Seminars in hematology 2010;47(2):148-55.
2010: Marion Hoffmann; Markus A Schirmer; Mladen V Tzvetkov; Markus Kreuz; Marita Ziepert; Leszek Wojnowski; Dieter Kube; Michael Pfreundschuh; Lorenz Trümper; Markus Loeffler; Jürgen Brockmöller
A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
Cancer research 2010;70(6):2328-38.
2010: Niels Murawski; Carsten Zwick; Michael Pfreundschuh
Unresolved issues in diffuse large B-cell lymphomas.
Expert review of anticancer therapy 2010;10(3):387-402.
2010: Yao-Tseng Chen; Amy Chadburn; Peishan Lee; Melinda Hsu; Erika Ritter; April Chiu; Sacha Gnjatic; Michael Pfreundschuh; Daniel M Knowles; Lloyd J Old
Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(7):3093-8.
2010: Gunter Assmann; Michael Pfreundschuh; Jan Voswinkel
Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers.
Clinical and experimental rheumatology 2010;28(1 Suppl 57):81-3.
2010: Sandra Grass; Klaus-Dieter Preuss; Michael Pfreundschuh
Autosomal-dominant inheritance of hyperphosphorylated paratarg-7.
The lancet oncology 2010;11(1):12.
2010: V Zimmer; Thomas Widmann; M Müller; M F Ong; J M Stein; Michael Pfreundschuh; Frank Lammert; K Roemer; G Assmann
Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease.
Digestion 2010;81(4):246-51.
2009: Niels Murawski; Michael Pfreundschuh
Differential therapy for diffuse large B-cell lymphoma with different cells of origin.
Onkologie 2009;32(12):711-2.
2009: M Nickelsen; M Ziepert; S Zeynalova; Bertram Glaß; B Metzner; M Leithaeuser; H K Mueller-Hermelink; Michael Pfreundschuh; Norbert Schmitz
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(12):1977-84.
2009: Heinz-Wolfram Bernd; Marita Ziepert; Christoph Thorns; Wolfram Klapper; Hans-Heinrich Wacker; Michael Hummel; Harald Stein; Martin-Leo Hansmann; German Ott; Andreas Rosenwald; Hans Konrad Müller-Hermelink; Thomas F E Barth; Peter Möller; Sergio B Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Silvia Höller; Markus Loeffler; Alfred C Feller
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.
Haematologica 2009;94(11):1569-80.
2009: Sandra Grass; Klaus-Dieter Preuss; Manfred Ahlgrimm; Natalie Fadle; Evi Regitz; Claudia Pfoehler; Niels Murawski; Michael Pfreundschuh
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
The lancet oncology 2009;10(10):950-6.
2009: Niels Murawski; Michael Pfreundschuh
Rituximab maintenance therapy in central nervous system lymphoma?
Leukemia & lymphoma 2009;50(10):1555-6.
2009: Carsten Zwick; Klaus-Dieter Preuss; Boris Kubuschok; Gerhard Held; Manfred Ahlgrimm; Joerg Bittenbring; Joerg Schubert; Frank Neumann; Michael Pfreundschuh
Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.
Annals of hematology 2009;88(10):999-1003.
2009: Andreas Engert; Volker Diehl; Jeremy Franklin; Andreas Lohri; Bernd Dörken; Wolf-Dieter Ludwig; Peter Koch; Mathias Hänel; Michael Pfreundschuh; Martin Wilhelm; Lorenz Trümper; Walter-Erich Aulitzky; Martin Bentz; Mathias Rummel; Orhan Sezer; Hans Konrad Müller-Hermelink; Dirk Hasenclever; Markus Loeffler
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4548-54.
2009: Nils Schoof; Frederike von Bonin; S Zeynalova; M Ziepert; Wolfram Jung; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Martin Hafner
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(9):1548-54.
2009: Carsten Zwick; Gerhard Held; Vera Hammermeister; Adnan Alahmad; Boris Kubuschok; Joerg Bittenbring; Manfred Ahlgrimm; Frank Neumann; Klaus-Dieter Preuss; Michael Pfreundschuh
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.
Journal of cancer research and clinical oncology 2009;135(9):1207-13.
2009: Norbert Schmitz; Samira Zeynalova; Markus Loeffler; Michael Pfreundschuh
Response: Intrathecal methotrexate and central nervous system events.
Blood 2009;114(9):1999-2000.
2009: Frank Neumann; Christine Sturm; Martin Hülsmeyer; Nina Dauth; Philippe Guillaume; Immanuel F Luescher; Michael Pfreundschuh; Gerhard Held
Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
Immunology letters 2009;125(2):86-92.
2009: John P Leonard; Michael E Williams; Andre Goy; Steven Grant; Michael Pfreundschuh; Steve T Rosen; John W Sweetenham
Mantle cell lymphoma: biological insights and treatment advances.
Clinical lymphoma & myeloma 2009;9(4):267-77.
2009: Klaus-Dieter Preuss; Michael Pfreundschuh; Manfred Ahlgrimm; Natalie Fadle; Evi Regitz; Niels Murawski; Sandra Grass
A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS.
International journal of cancer. Journal international du cancer 2009;125(3):656-61.
2009: Volkmar Boehme; Norbert Schmitz; Samira Zeynalova; Markus Loeffler; Michael Pfreundschuh
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood 2009;113(17):3896-902.
2009: Gerhard Held; Michael Pfreundschuh
Hematology: germinal center or nongerminal center DLBCL?
Nature reviews. Clinical oncology 2009;6(4):188-90.
2009: Annina Herrmann; Eva Hoster; Thomas Zwingers; Günter Brittinger; Marianne Engelhard; Peter Meusers; Marcel Reiser; Roswitha Forstpointner; Bernd Metzner; Norma Peter; Bernhard Wörmann; Lorenz Trümper; Michael Pfreundschuh; Hermann Einsele; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Improvement of overall survival in advanced stage mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):511-8.
2009: Gunter Assmann; Olaf Kueck; Timm Kirchhoff; Herbert Rosenthal; Jan Voswinkel; Michael Pfreundschuh; Henning Zeidler; Annette D Wagner
Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study.
Arthritis research & therapy 2009;11(5):R140.
2009: Gunter Assmann; Christian Werner; Markus Herrmann; Dunja Momber; Thomas Krenn; Daniela Lothschütz; Lars Fischer; Sandra Hess; Ralf Ketter; Wolfgang Feiden; Stefan Jung; Wolfgang Herrmann; Jörg Schubert; Michael Pfreundschuh; Thomas Widmann
Detection of Meningeosis neoplastica by real-time quantitation of telomerase activity.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(10):1271-6.
2009: Ruth Pettengell; Matti Aapro; Ercole Brusamolino; Dolores Caballero; Bertrand Coiffier; Michael Pfreundschuh; Marek Trneny; Jan Walewski
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
Clinical drug investigation 2009;29(8):491-513.
2008: Esa Jantunen; Carmen Canals; Alessandro Rambaldi; Gert Ossenkoppele; Bernardino Allione; Didier Blaise; Eulogio Conde; Hervè Tilly; Gordon Cook; Fiona Clark; Andrea Gallamini; Andrew Haynes; Nicolas Mounier; Peter Dreger; Michael Pfreundschuh; Anna Sureda
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
Haematologica 2008;93(12):1837-42.
2008: Gerhard Held; Frank Neumann; Christine Sturm; Lars Kaestner; Nina Dauth; Diederik R de Bruijn; Christoph Renner; Peter Lipp; Michael Pfreundschuh
Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
International journal of cancer. Journal international du cancer 2008;123(8):1841-7.
2008: Anja Roehle; Kai P Hoefig; Dirk Repsilber; Christoph Thorns; Marita Ziepert; Kai O Wesche; Marlen Thiere; Markus Loeffler; Wolfram Klapper; Michael Pfreundschuh; András Matolcsy; Heinz-Wolfram Bernd; Lilla Reiniger; Hartmut Merz; Alfred C Feller
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.
British journal of haematology 2008;142(5):732-44.
2008: Christian Werner; Milad Hanhoun; Thomas Widmann; Andrey Kazakov; Alexander Semenov; Janine Pöss; Johann Bauersachs; Thomas Thum; Michael Pfreundschuh; Patrick Müller; Judith Haendeler; Michael Böhm; Ulrich Laufs
Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis.
Journal of the American College of Cardiology 2008;52(6):470-82.
2008: G Held; J Schubert; Michael Pfreundschuh
[Treatment of hematological malignancies with monoclonal antibodies].
Der Internist 2008;49(8):929-30, 932-4, 936-7.
2008: Martin Hafner; Thanh-Duc Hua; Frederike von Bonin; Nils Schoof; Samira Zeynalova; M Klöss; Daniela Gocht; Bernd Potthoff; Mladen Tzvetkov; Jürgen Brockmöller; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper
Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3777-84.
2008: Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood 2008;111(12):5486-95.
2008: Michael Pfreundschuh; Anthony Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
The lancet oncology 2008;9(5):435-44.
2008: M Ziepert; Rudolf Schmits; Lorenz Trümper; Michael Pfreundschuh; Markus Loeffler
Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(4):752-62.
2008: Lorenz Trümper; Carsten Zwick; M Ziepert; Karin Hohloch; Rudolf Schmits; Martin Mohren; Rüdiger Liersch; Martin Bentz; U Graeven; U Wruck; M Hoffmann; B Metzner; Dirk Hasenclever; Markus Loeffler; Michael Pfreundschuh
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):538-44.
2008: Michael Pfreundschuh; Carsten Zwick; S Zeynalova; U Dührsen; K-H Pflüger; T Vrieling; R Mesters; H-G Mergenthaler; H Einsele; Martin Bentz; E Lengfelder; Lorenz Trümper; C Rübe; Norbert Schmitz; Markus Loeffler
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):545-52.
2008: Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glaß; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
The lancet oncology 2008;9(2):105-16.
2008: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel Van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Blood 2008;111(2):558-65.
2008: Thomas Widmann; Urban Sester; Barbara C Gärtner; Jörg Schubert; Michael Pfreundschuh; Hans Köhler; Martina Sester
Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
PloS one 2008;3(11):e3634.
2008: Koen van Besien; Christian Gisselbrecht; Michael Pfreundschuh; Emanuele Zucca
Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
Leukemia & lymphoma 2008;49 Suppl 1():52-8.
2008: Joerg Bittenbring; Frédérique Parisot; Alain Wabo; Monika Mueller; Lynn Kerschenmeyer; Markus Kreuz; Lorenz Truemper; Olfert Landt; Alain Menzel; Michael Pfreundschuh; Klaus Roemer
MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.
BMC cancer 2008;8():116.
2008: Thomas Widmann; Harald Kneer; Jochem König; Markus Herrmann; Michael Pfreundschuh
Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.
Experimental hematology 2008;36(1):104-10.
2007: Carsten Zwick; Beate Gleissner; Michael Pfreundschuh
Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
Clinical lymphoma & myeloma 2007;8 Suppl 2():S43-9.
2007: Sandra Hess; Michael Pfreundschuh; Beate Gleissner
Notch signaling.
Journal of neurosurgery 2007;107(5):1060-1; author reply 1061-2.
2007: Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3495-502.
2007: Klaus-Dieter Preuss; Gerhard Held; Boris Kubuschok; Chun-Zhu Hung; Natalia Malatsidze; Mathias Wagner; Michael Pfreundschuh
Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS.
International journal of cancer. Journal international du cancer 2007;121(2):459-61.
2007: Gerhard Held; Andreas Wadle; Nina Dauth; Guillaume Stewart-Jones; Christine Sturm; Markus Thiel; Carsten Zwick; Detlef Dieckmann; Gerold Schuler; Hennie Hoogenboom; Frédéric Lévy; Vincenzo Cerundolo; Michael Pfreundschuh; Christoph Renner
MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
European journal of immunology 2007;37(7):2008-17.
2007: Inka Seil; Claudia Frei; Holger Sültmann; Shirley K Knauer; Knut Engels; Elke Jäger; Kurt Zatloukal; Michael Pfreundschuh; Alexander Knuth; Yao Tseng-Chen; Achim A Jungbluth; Roland H Stauber; Dirk Jäger
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
International journal of cancer. Journal international du cancer 2007;120(12):2635-42.
2007: Thomas Widmann; Markus Herrmann; Naim Taha; Jochem König; Michael Pfreundschuh
Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis.
Experimental hematology 2007;35(6):939-46.
2007: Rüdiger Hehlmann; Ute Berger; Markus Pfirrmann; Hermann Heimpel; Andreas Hochhaus; Joerg Hasford; Hans-Jochem Kolb; Tanja Lahaye; Ole Maywald; Andreas Reiter; Dieter K Hossfeld; Christoph Huber; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler; Christoph Nerl; Max Solenthaler; Mariele E Goebeler; Martin Griesshammer; Thomas Fischer; Stephan Kremers; Hartmut Eimermacher; Michael Pfreundschuh; Wolf-Dietrich Hirschmann; Klaus Lechner; Barbara Wassmann; Christiane Falge; Hartmut H Kirchner; Alois Gratwohl
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood 2007;109(11):4686-92.
2007: Martin Hafner; TD Hua; M Klöss; Bettina Kulle; Jürgen Brockmöller; Leszek Wojnowski; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper
The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma.
Genes and immunity 2007;8(2):164-7.
2007: Claudia Pföhler; Klaus-Dieter Preuss; Wolfgang Tilgen; Alexandra Stark; Evi Regitz; Natalie Fadle; Michael Pfreundschuh
Mitofilin and titin as target antigens in melanoma-associated retinopathy.
International journal of cancer. Journal international du cancer 2007;120(4):788-95.
2007: V Boehme; S Zeynalova; Marita Kloess; Markus Loeffler; U Kaiser; Michael Pfreundschuh; Norbert Schmitz
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):149-57.
2006: Gerhard Held; Joerg Schubert; Marcel Reiser; Michael Pfreundschuh
Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
Seminars in hematology 2006;43(4):221-9.
2006: Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Trumper; Marcel Reiser; Hannes Wandt; Eva Lengfelder; Michael Unterhalt; Wolfgang Hiddemann
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Cancer 2006;107(5):1014-22.
2006: Gerhard Held; Viola Pöschel; Michael Pfreundschuh
Rituximab for the treatment of diffuse large B-cell lymphomas.
Expert review of anticancer therapy 2006;6(8):1175-86.
2006: Andreas Wadle; Boris Kubuschok; Jochen Imig; Beate Wuellner; Christine Wittig; Carsten Zwick; Axel Mischo; Kristin Waetzig; Bernd F.M. Romeike; Werner Lindemann; Martin Schilling; Michael Pfreundschuh; Christoph Renner
Serological immune response to cancer testis antigens in patients with pancreatic cancer.
International journal of cancer. Journal international du cancer 2006;119(1):117-25.
2006: Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noël Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
The lancet oncology 2006;7(5):379-91.
2006: Bertram Glaß; Marita Kloess; Martin Bentz; Günter Schlimok; Wolfgang E Berdel; Alfred Feller; Lorenz Trümper; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.
Blood 2006;107(8):3058-64.
2006: Michael Pfreundschuh
Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Nature clinical practice. Oncology 2006;3(4):184-5.
2006: Boris Kubuschok; Frank Neumann; Rainer Breit; Martina Sester; Claudia Schormann; Claudia Wagner; Urban Sester; Frank Hartmann; Mathias Wagner; Klaus Remberger; Martin Schilling; Michael Pfreundschuh
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1365-72.
2006: Axel Mischo; Boris Kubuschok; Kubilay Ertan; Klaus-Dieter Preuss; Bernd F.M. Romeike; Evi Regitz; Claudia Schormann; Diederik de Bruijn; Andreas Wadle; Frank Neumann; Werner Schmidt; Christoph Renner; Michael Pfreundschuh
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.
International journal of cancer. Journal international du cancer 2006;118(3):696-703.
2006: Norbert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E Berdel; Bernd Metzner; Bernd Dorken; Michael Kneba; Lorenz Trumper; Markus Loeffler; Michael Pfreundschuh; Bertram Glaß
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Cancer 2006;106(1):136-45.
2006: Klaus-Dieter Preuss; Evi Regitz; Frank Neumann; Michael Pfreundschuh
B-cell epitopes from the cancer testis antigen NY-ESO-1.
International journal of cancer. Journal international du cancer 2006;118(1):253.
2005: Andreas Wadle; Axel Mischo; Philipp P Henrich; Frank Stenner-Liewen; Frank Stenner-Lieven; Christoph Scherer; Jochen Imig; Gabriele Petersen; Michael Pfreundschuh; Christoph Renner
Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activity.
International journal of cancer. Journal international du cancer 2005;117(6):896-904.
2005: Leszek Wojnowski; Bettina Kulle; Markus Schirmer; Gregor Schlüter; Albrecht Schmidt; Albert Rosenberger; Stefan Vonhof; Heike Bickeböller; Mohammad R Toliat; Eun-Kyung Suk; Mladen Tzvetkov; Anke Kruger; Silvia Seifert; Marita Kloess; Heidi Hahn; Markus Loeffler; Peter Nürnberg; Michael Pfreundschuh; Lorenz Trümper; Jürgen Brockmöller; Gerd Hasenfuss
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Circulation 2005;112(24):3754-62.
2005: Michael Pfreundschuh
Mature T-cell and NK/T-cell neoplasms.
Clinical advances in hematology & oncology : H&O 2005;3(11):suppl 8-9.
2005: Frank Neumann; Claudia Wagner; Klaus-Dieter Preuss; Boris Kubuschok; Claudia Schormann; Stefan Stevanovic; Michael Pfreundschuh
Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.
Blood 2005;106(9):3105-13.
2005: Andreas Wadle; Axel Mischo; Jochen Imig; Beate Wüllner; Dan Hensel; Kristin Wätzig; Frank Neumann; Boris Kubuschok; Werner Schmidt; Lloyd J Old; Michael Pfreundschuh; Christoph Renner
Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library.
International journal of cancer. Journal international du cancer 2005;117(1):104-13.
2005: Thomas Alexander Widmann; Barbara Willmann; Michael Pfreundschuh; Dietrich W Beelen
Influence of telomere length on short-term recovery after allogeneic stem cell transplantation.
Experimental hematology 2005;33(10):1257-61.
2005: Heike Liewen; Ivo Meinhold-Heerlein; Vasco Oliveira; Robert Schwarzenbacher; Guorong Luo; Andreas Wadle; Martin Jung; Michael Pfreundschuh; Frank Stenner-Liewen
Characterization of the human GARP (Golgi associated retrograde protein) complex.
Experimental cell research 2005;306(1):24-34.
2005: Robert Dinser; Aleksandar Grgic; Yoo-Jin Kim; Michael Pfreundschuh; Jörg Schubert
Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft.
European journal of haematology 2005;74(5):438-41.
2005: Rudolf Schmits; Norbert Schmitz; Michael Pfreundschuh
The best treatment for diffuse large B-cell lymphoma: a German perspective.
Oncology (Williston Park, N.Y.) 2005;19(4 Suppl 1):16-25.
2005: Rudolf Schmits; Frank Hartmann; Michael Pfreundschuh
Advances in molecular biology diagnostic and treatment of B-cell malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii105.
2004: Martin Schlapschy; Helga Gruber; Oliver Gresch; Claudia Schäfer; Christoph Renner; Michael Pfreundschuh; Arne Skerra
Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
Protein engineering, design & selection : PEDS 2004;17(12):847-60.
2004: Frank Neumann; Claudia Wagner; Stefan Stevanovic; Boris Kubuschok; Claudia Schormann; Axel Mischo; Kubilay Ertan; Werner Schmidt; Michael Pfreundschuh
Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
International journal of cancer. Journal international du cancer 2004;112(4):661-8.
2004: Gerhard Held; Mitsutoshi Matsuo; Malka Epel; Sacha Gnjatic; Gerd Ritter; Sang-Yull Lee; Tsin Yee Tai; Cyrille Cohen; Lloyd J Old; Michael Pfreundschuh; Yoram Reiter; Hennie Hoogenboom; Christoph Renner
Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
European journal of immunology 2004;34(10):2919-29.
2004: Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Blood 2004;104(3):634-41.
2004: Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glaß; Christian Rübe; Markus Loeffler
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Blood 2004;104(3):626-33.
2004: Frank Neumann; Claudia Wagner; Boris Kubuschok; Stefan Stevanovic; Hans-Georg Rammensee; Michael Pfreundschuh
Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.
Cancer immunology, immunotherapy : CII 2004;53(7):589-99.
2004: Boris Kubuschok; Xiaoxiun Xie; Ralf Jesnowski; Klaus-Dieter Preuss; Bernd F.M. Romeike; Frank Neumann; Evi Regitz; Georg Pistorius; Martin Schilling; Peter Scheunemann; Jakob R Izbicki; J-Matthias Löhr; Michael Pfreundschuh
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.
International journal of cancer. Journal international du cancer 2004;109(4):568-75.
2004: Stefan Bauer; Nicole Adrian; Barbara Williamson; Con Panousis; Natalie Fadle; Joanna Smerd; Ilknur Fettah; Andrew M Scott; Michael Pfreundschuh; Christoph Renner
Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(6):3930-9.
2003: Claudia Wagner; Frank Neumann; Boris Kubuschok; Evi Regitz; Axel Mischo; Stefan Stevanovic; Michael Friedrich; Werner Schmidt; Hans-Georg Rammensee; Michael Pfreundschuh
Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Cancer immunity 2003;3():18.
2003: Philipp Niemeyer; Ozlem Türeci; Thomas Eberle; Norbert Graf; Michael Pfreundschuh; Ugur Sahin
Expression of serologically identified tumor antigens in acute leukemias.
Leukemia research 2003;27(7):655-60.
2003: Axel Mischo; Andreas Wadle; Kristin Wätzig; Dirk Jäger; Elisabeth Stockert; Darren Santiago; Gerd Ritter; Evi Regitz; Elke Jäger; Alex Knuth; Lloyd J Old; Michael Pfreundschuh; Christoph Renner
Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.
Cancer immunity 2003;3():5.
2003: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Markus Loeffler
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
The New England journal of medicine 2003;348(24):2386-95.
2003: A Wunderlich; Marita Kloess; Marcel Reiser; Christian Rudolph; Lorenz Truemper; S Bittner; H Schmalenberg; Rudolf Schmits; Michael Pfreundschuh; Markus Loeffler
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):881-93.
2003: Xiaoxun Xie; Hans-Heinrich Wacker; Shaoming Huang; Evi Regitz; Klaus-Dieter Preuss; Bernd F.M. Romeike; Reza Parwaresch; Markus Tiemann; Michael Pfreundschuh
Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):167-73.
2003: Jürgen Krauss; Michaela A E Arndt; Michael Pfreundschuh
Application of recombinant antibodies in cancer patients.
Methods in molecular biology (Clifton, N.J.) 2003;207():27-53.
2002: Shaoming Huang; Klaus-Dieter Preuss; Xiaoxun Xie; Evi Regitz; Michael Pfreundschuh
Analysis of the antibody repertoire of lymphoma patients.
Cancer immunology, immunotherapy : CII 2002;51(11-12):655-62.
2002: Ugur Sahin; Frank Neumann; Ozlem Tureci; Rudolf Schmits; Franck Perez; Michael Pfreundschuh
Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells.
Blood 2002;100(12):4139-45.
2002: Ulrich Kaiser; Irmgard Uebelacker; Ulrich Abel; Josef Birkmann; Lorenz Trümper; Harald Schmalenberg; Tunca Karakas; Bernd Metzner; Dieter K Hossfeld; Helge G Bischoff; Astrid Franke; Marcel Reiser; Peter Müller; Luisa Mantovani; Marc Grundeis; Frank Rothmann; Cay-Uwe von Seydewitz; Rolf M Mesters; Ernst U Steinhauer; Dorothea Krahl; Kurt Schumacher; Michael Kneba; Baudis Michael; Norbert Schmitz; Rüdiger Pfab; Hubert Köppler; Reza Parwaresch; Michael Pfreundschuh; Klaus Havemann
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4413-9.
2002: Bertrand Coiffier; Michael Pfreundschuh; Rolf Stahel; Julie Vose; Pier Luigi Zinzani
Aggressive lymphoma: improving treatment outcome with rituximab.
Anti-cancer drugs 2002;13 Suppl 2():S43-50.
2002: Lorenz Trümper; Markus Menges; Heiner Daus; Daniel Köhler; Jan-Olaf Reinhard; Michael Sackmann; Cornelius Moser; Alexandra Sek; Georg Jacobs; Martin Zeitz; Michael Pfreundschuh
Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4331-7.
2002: Klaus-Dieter Preuss; Carsten Zwick; Claudia Bormann; Frank Neumann; Michael Pfreundschuh
Analysis of the B-cell repertoire against antigens expressed by human neoplasms.
Immunological reviews 2002;188():43-50.
2002: Guorong Luo; Shaoming Huang; Xiaoxun Xie; Elisabeth Stockert; Yao-Tseng Chen; Boris Kubuschok; Michael Pfreundschuh
Expression of cancer-testis genes in human hepatocellular carcinomas.
Cancer immunity 2002;2():11.
2002: Ozlem Türeci; Ugur Sahin; Michael Koslowski; Benedikt Buss; Carolin Bell; Pia Ballweber; Carsten Zwick; Thomas Eberle; Margit A Zuber; Carlos Villena-Heinsen; Gerhard Seitz; Michael Pfreundschuh
A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing.
Oncogene 2002;21(24):3879-88.
2002: Boris Kubuschok; Rudolf Schmits; Frank Hartmann; Christiane Cochlovius; Rainer Breit; Jochem König; Georg Pistorius; Martin Schilling; Christoph Renner; Michael Pfreundschuh
Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Human gene therapy 2002;13(7):815-27.
2002: Rudolf Schmits; Björn Cochlovius; Gerhard Treitz; Evi Regitz; Ralf Ketter; Klaus-Dieter Preuss; Bernd F.M. Romeike; Michael Pfreundschuh
Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas.
International journal of cancer. Journal international du cancer 2002;98(1):73-7.
2002: Maha Ayyoub; Stefan Stevanovic; Ugur Sahin; Philippe Guillaume; Catherine Servis; Donata Rimoldi; Danila Valmori; Pedro Romero; Jean-Charles Cerottini; Hans-Georg Rammensee; Michael Pfreundschuh; Daniel Speiser; Frédéric Lévy
Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(4):1717-22.
2002: Rudolf Schmits; Boris Kubuschok; S Schuster; Klaus-Dieter Preuss; Michael Pfreundschuh
Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica.
Clinical and experimental immunology 2002;127(2):379-85.
2002: Markus Sieber; Hans Tesch; Beate Pfistner; Ulrich Rueffer; Bernd Lathan; Oana Brosteanu; Ursula Paulus; Tina Koch; Michael Pfreundschuh; Markus Loeffler; Andreas Engert; Andreas Josting; Jürgen Wolf; Dirk Hasenclever; Jeremy Franklin; Eckhart Duehmke; Axel Georgii; Klaus-Peter Schalk; Hartmut Kirchner; Gottfried Doelken; Reinhold Munker; Peter Koch; Richard Herrmann; richard greil; Anna Paola Anselmo; Volker Diehl
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):476-84.
2001: X Xie; Rudolf Schmits; Christoph Renner; D Preuss; Boris Kubuschok; Michael Pfreundschuh
Systematic search and molecular characterization of the antigenic targets of myeloma immunoglobulins: a monoclonal IgA from a female patient targeting sperm-specific cylicin II.
Cancer immunity 2001;1():11.
2001: Lorenz Trümper; Wolfram Jung; Heiner Daus; Gunhild Mechtersheimer; Frederike von Bonin; Michael Pfreundschuh
Assessment of clonality of rosetting T lymphocytes in Hodgkin's disease by single-cell polymerase chain reaction: detection of clonality in a polyclonal background in a case of lymphocyte predominance Hodgkin's disease.
Annals of hematology 2001;80(11):653-61.
2001: Andreas Wadle; G Thiel; Axel Mischo; Volker Jung; Michael Pfreundschuh; Christoph Renner
Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1.
Oncogene 2001;20(41):5920-9.
2001: F Hartmann; G Jacobs; H Gotto; J Schwamborn; Michael Pfreundschuh
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Leukemia & lymphoma 2001;42(3):347-55.
2001: F Hartmann; C Renner; W Jung; L da Costa; S Tembrink; G Held; A Sek; J König; S Bauer; M Kloft; Michael Pfreundschuh
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1873-81.
2001: Eckhart Dühmke; Jeremy Franklin; Michael Pfreundschuh; Susanne Sehlen; Normann Willich; Ursula Rühl; Rolf-Peter Müller; P Lukas; A Atzinger; Ursula Paulus; Bernd Lathan; U Rüffer; Markus Sieber; Jürgen Wolf; Andreas Engert; Axel Georgii; Susanne Staar; Richard Herrmann; M Beykirch; Hartmut Kirchner; A Emminger; richard greil; E Fritsch; Peter Koch; A Drochtert; Oana Brosteanu; Dirk Hasenclever; Markus Loeffler; Volker Diehl
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2905-14.
2001: C Renner; Boris Kubuschok; Lorenz Trümper; Michael Pfreundschuh
Clinical approaches to vaccination in oncology.
Annals of hematology 2001;80(5):255-66.
2001: C Renner; I Stehle; Fook-Thean Lee; Cathrine Hall; Bruno Catimel; Edouard C Nice; Angela J Mountain; Angela Rigopoulos; Martin W Brechbiel; Michael Pfreundschuh; Andrew M Scott
Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Cancer immunology, immunotherapy : CII 2001;50(2):102-8.
2001: Michael Pfreundschuh; Dirk Hasenclever; Markus Loeffler; G Ehninger; Norbert Schmitz; Hartmut Kirchner; Peter Koch; Bernd Lathan; Ulrich Rueffer; Michael Sextro; Jeremy Franklin; Hans Tesch; Volker Diehl
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):471-7.
2001: M Küpper; Stefan Joos; Frederike von Bonin; Heiner Daus; Michael Pfreundschuh; Peter Lichter; Lorenz Trümper
MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies.
British journal of haematology 2001;112(3):768-75.
2001: Rudolf Schmits; Bertram Glaß; Lorenz Trümper; Michael Pfreundschuh
Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
Annals of hematology 2001;80 Suppl 3():B77-83.
2001: Michael Pfreundschuh
Lymphoma 2000. The First International Symposium on Biology and Treatment of Aggressive Lymphomas: The stagnation seems to be over.
Annals of hematology 2001;80 Suppl 3():B1-2.
2000: U Sahin; Michael Koslowski; Ozlem Türeci; Thomas Eberle; Carsten Zwick; Bernd F.M. Romeike; Jean Richard Moringlane; K Schwechheimer; Wolfgang Feiden; Michael Pfreundschuh
Expression of cancer testis genes in human brain tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3916-22.
2000: Boris Kubuschok; Christiane Cochlovius; W Jung; Rudolf Schmits; Lorenz Trümper; Frank Hartmann; Christoph Renner; Michael Pfreundschuh
Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.
Cancer gene therapy 2000;7(9):1231-40.
2000: Henrik Thorlacius; B Vollmar; Y Guo; T W Mak; Michael Pfreundschuh; Michael D Menger; Rudolf Schmits
Lymphocyte function antigen 1 (LFA-1) mediates early tumour necrosis factor alpha-induced leucocyte adhesion in venules.
British journal of haematology 2000;110(2):424-9.
2000: C Renner; F Hartmann; W Jung; C Deisting; M Juwana; Michael Pfreundschuh
Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Cancer immunology, immunotherapy : CII 2000;49(3):173-80.
2000: Frank Stenner-Liewen; G Luo; Ugur Sahin; Ozlem Tureci; M Koslovski; I Kautz; Heike Liewen; Michael Pfreundschuh
Definition of tumor-associated antigens in hepatocellular carcinoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(3):285-90.
2000: Stefan Joos; M Küpper; Sibylle Ohl; Frederike von Bonin; Gunhild Mechtersheimer; Martin Bentz; P Marynen; Peter Möller; Michael Pfreundschuh; Lorenz Trümper; Peter Lichter
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Cancer research 2000;60(3):549-52.
2000: Michael Pfreundschuh
Exploitation of the B cell repertoire for the identification of human tumor antigens.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S3-7.
1999: Michaela A E Arndt; Jürgen Krauss; Sergey M Kipriyanov; Michael Pfreundschuh; Melvyn Little
A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
Blood 1999;94(8):2562-8.
1999: G Jacobs; E Tscholl; Alexandra Sek; Michael Pfreundschuh; Heiner Daus; Lorenz Trümper
Enrichment polymerase chain reaction for the detection of Ki-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands.
Journal of cancer research and clinical oncology 1999;125(7):395-401.
1999: S Bauer; C Renner; J P Juwana; G Held; S Ohnesorge; K Gerlach; Michael Pfreundschuh
Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
Cancer research 1999;59(8):1961-5.
1999: J P Juwana; Paula Maria Henderikx; Axel Mischo; Andreas Wadle; Natalie Fadle; K Gerlach; Jan-Willem Arends; Hennie Hoogenboom; Michael Pfreundschuh; Christoph Renner
EB/RP gene family encodes tubulin binding proteins.
International journal of cancer. Journal international du cancer 1999;81(2):275-84.
1999: Ozlem Türeci; Ugur Sahin; Carsten Zwick; Frank Neumann; Michael Pfreundschuh
Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens.
Hybridoma 1999;18(1):23-8.
1998: Hans Tesch; Volker Diehl; Bernd Lathan; Dirk Hasenclever; Markus Sieber; U Rüffer; Andreas Engert; Jeremy Franklin; Michael Pfreundschuh; K P Schalk; G Schwieder; G Wulf; Gottfried Dölken; P Worst; Peter Koch; Norbert Schmitz; U Bruntsch; C Tirier; U Müller; Markus Loeffler
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Blood 1998;92(12):4560-7.
1998: Lorenz Trümper; Michael Pfreundschuh; F V Bonin; Heiner Daus
Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals.
British journal of haematology 1998;103(4):1138-44.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; J U Rueffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; E Duehmke; Axel Georgii; Markus Loeffler
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3810-21.
1998: F Hartmann; C Renner; W Jung; Michael Pfreundschuh
Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
Leukemia & lymphoma 1998;31(3-4):385-92.
1998: Heiner Daus; C Ozbek; D Saage; Bruno Scheller; HJ Schieffer; Michael Pfreundschuh; A Gause
Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation.
Cardiology 1998;90(2):83-8.
1998: Ozlem Türeci; Yao-Tseng Chen; Ugur Sahin; Ali O Güre; Carsten Zwick; C Villena; S Tsang; Gerhard Seitz; Lloyd J Old; Michael Pfreundschuh
Expression of SSX genes in human tumors.
International journal of cancer. Journal international du cancer 1998;77(1):19-23.
1998: Ozlem Türeci; Ugur Sahin; E Vollmar; S Siemer; E Göttert; G Seitz; Anna-Kaisa Parkkila; Gul N Shah; Jeffrey H Grubb; Michael Pfreundschuh; William S Sly
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(13):7608-13.
1998: Matthew J Scanlan; Yao-Tseng Chen; Barbara Williamson; Ali O Gure; Elisabeth Stockert; JD Gordan; Ozlem Türeci; Ugur Sahin; Michael Pfreundschuh; Lloyd J Old
Characterization of human colon cancer antigens recognized by autologous antibodies.
International journal of cancer. Journal international du cancer 1998;76(5):652-8.
1998: C Renner; L Trümper; JP Pfitzenmeier; U Loftin; K Gerlach; I Stehle; Andreas Wadle; Michael Pfreundschuh
Differential mRNA display at the single-cell level.
BioTechniques 1998;24(5):720-2, 724.
1998: Ozlem Türeci; Ugur Sahin; Carsten Zwick; Michael Koslowski; G Seitz; Michael Pfreundschuh
Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(9):5211-6.
1998: Anja Mehl-Lautscham; N Fischer; M Rowe; F Hartmann; Heiner Daus; Lorenz Trümper; Michael Pfreundschuh; N Müller-Lantzsch; Friedrich A Grässer
Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma.
International journal of cancer. Journal international du cancer 1998;76(2):194-200.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; JU Rüffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; Eckhart Dühmke; Axel Georgii; Markus Loeffler
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S67-71.
1997: C Renner; F Hartmann; Michael Pfreundschuh
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Cancer immunology, immunotherapy : CII 1997;45(3-4):184-6.
1997: Ali O Gure; Ozlem Türeci; Ugur Sahin; S Tsang; Matthew J Scanlan; Elke Jäger; Alexander Knuth; Michael Pfreundschuh; Lloyd J Old; Yao-Tseng Chen
SSX: a multigene family with several members transcribed in normal testis and human cancer.
International journal of cancer. Journal international du cancer 1997;72(6):965-71.
1997: C Renner; JP Pfitzenmeier; K Gerlach; G Held; S Ohnesorge; U Sahin; S Bauer; Michael Pfreundschuh
RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(3):1276-83.
1997: C Renner; G Held; S Ohnesorge; S Bauer; K Gerlach; JP Pfitzenmeier; Michael Pfreundschuh
Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies.
Immunobiology 1997;197(1):122-32.
1997: Markus Loeffler; Volker Diehl; Michael Pfreundschuh; Ursula Rühl; Dirk Hasenclever; Hiltrud Nisters-Backes; Markus Sieber; Hans Tesch; Jeremy Franklin; W Geilen; H Bartels; C Cartoni; Gottfried Dölken; J Enzian; R Fuchs; W Gassmann; H Gerhartz; U Hagen-Aukamp; E Hiller; H Hinkelbein; W Hinterberger; Hartmut Kirchner; Peter Koch; B Krüger; EW Schwarze
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2275-87.
1997: C Renner; G Held; S Ohnesorge; S Bauer; K Gerlach; JP Pfitzenmeier; Michael Pfreundschuh
Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells.
Cancer immunology, immunotherapy : CII 1997;44(2):70-6.
1997: F Hartmann; C Renner; W Jung; C Deisting; M Juwana; B Eichentopf; M Kloft; Michael Pfreundschuh
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Blood 1997;89(6):2042-7.
1997: Yao-Tseng Chen; Matthew J Scanlan; Ugur Sahin; Ozlem Türeci; Ali O Gure; S Tsang; Barbara Williamson; Elisabeth Stockert; Michael Pfreundschuh; Lloyd J Old
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):1914-8.
1997: F Hartmann; Michael Pfreundschuh
[Oncology '96].
Medizinische Klinik (Munich, Germany : 1983) 1997;92(2):83-100.
1997: Volker Diehl; Markus Sieber; U Rüffer; Bernd Lathan; Dirk Hasenclever; Michael Pfreundschuh; Markus Loeffler; D Lieberz; Peter Koch; M Adler; Hans Tesch
BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):143-8.
1997: A Gause; K Gundlach; G Carbon; Heiner Daus; Lorenz Trümper; Michael Pfreundschuh
Analysis of VH gene rearrangements from synovial B cells of patients with rheumatoid arthritis reveals infiltration of the synovial membrane by memory B cells.
Rheumatology international 1997;17(4):145-50.
1997: Lorenz Trümper; Heiner Daus; H Merz; Frederike von Bonin; U Loftin; Christiane Cochlovius; Peter Möller; Alfred C Feller; Michael Pfreundschuh
NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: results from single-cell cDNA analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 2():83-7.
1996: Ozlem Türeci; Ugur Sahin; I Schobert; M Koslowski; H Scmitt; H J Schild; F Stenner; G Seitz; H G Rammensee; Michael Pfreundschuh
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.
Cancer research 1996;56(20):4766-72.
1996: Jan Voswinkel; Lorenz Trümper; G Carbon; T Hopf; Michael Pfreundschuh; Angela Gause
Evidence for a selected humoral immune response encoded by VH4 family genes in the synovial membrane of a patient with rheumatoid arthritis (RA).
Clinical and experimental immunology 1996;106(1):5-12.
1996: C Renner; S Ohnesorge; G Held; S Bauer; W Jung; JP Pfitzenmeier; Michael Pfreundschuh
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
Blood 1996;88(1):236-41.
1996: F Hartmann; Michael Pfreundschuh; Volker Diehl
[Prognosis and therapy of Hodgkin's disease].
Medizinische Klinik (Munich, Germany : 1983) 1996;91 Suppl 3():75-9.
1996: Michael Pfreundschuh
['94 oncology update].
Medizinische Klinik (Munich, Germany : 1983) 1996;91 Suppl 1():7-22.
1996: C Renner; S Bauer; Ugur Sahin; W Jung; R van Lier; G Jacobs; G Held; Michael Pfreundschuh
Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Blood 1996;87(7):2930-7.
1996: Lorenz Trümper; Michael Pfreundschuh; G Jacobs; F von Bonin; U Loftin; P Möller; Heiner Daus
N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells: results from single cell polymerase chain-reaction examinations.
Leukemia 1996;10(4):727-30.
1996: B Koch; P Lemmermeier; Angela Gause; H v Wilmowsky; J Heisel; Michael Pfreundschuh
Demonstration of interleukin-1beta and interleukin-6 in cells of synovial fluids by flow cytometry.
European journal of medical research 1996;1(5):244-8.
1996: Lorenz Trümper; Heiner Daus; Angela Gause; Michael Pfreundschuh
Immunoglobulin V genes in Reed-Sternberg cells.
The New England journal of medicine 1996;334(6):404-5; author reply 405-6.
1996: M Zdichavsky; C Schorpp; A Nickels; B Koch; Michael Pfreundschuh; Angela Gause
Analysis of bcl-2+ lymphocyte subpopulations in inflammatory synovial infiltrates by a double-immunostaining technique.
Rheumatology international 1996;16(4):151-7.
1996: F Hartmann; C Renner; W Jung; Ugur Sahin; Michael Pfreundschuh
Treatment of Hodgkin's disease with bispecific antibodies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():143-6.
1996: M Küpper; U Loftin; F von Bonin; Angela Gause; Michael Pfreundschuh; Heiner Daus; Lorenz Trümper
Single cell PCR for the analysis of Hodgkin's disease: four years later.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():35-9.
1996: Ugur Sahin; S Kraft-Bauer; S Ohnesorge; Michael Pfreundschuh; C Renner
Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Cancer immunology, immunotherapy : CII 1996;42(1):9-14.
1995: Ugur Sahin; Ozlem Türeci; H Schmitt; B Cochlovius; T Johannes; R Schmits; F Stenner; G Luo; I Schobert; Michael Pfreundschuh
Human neoplasms elicit multiple specific immune responses in the autologous host.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11810-3.
1995: Volker Diehl; Markus Loeffler; Michael Pfreundschuh; U Ruehl; Dirk Hasenclever; Hiltrud Nisters-Backes; Markus Sieber; K Smith; Hans Tesch; W Geilen
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(9):901-10.
1995: C Renner; Michael Pfreundschuh
Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Journal of hematotherapy 1995;4(5):447-51.
1995: Angela Gause; K Gundlach; M Zdichavsky; G Jacobs; B Koch; T Hopf; Michael Pfreundschuh
The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane.
European journal of immunology 1995;25(10):2775-82.
1995: C Renner; W Jung; Ugur Sahin; R van Lier; Michael Pfreundschuh
The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies.
European journal of immunology 1995;25(7):2027-33.
1995: Heiner Daus; Lorenz Trümper; J Roth; F von Bonin; P Möller; Angela Gause; Michael Pfreundschuh
Hodgkin and Reed-Sternberg cells do not carry T-cell receptor gamma gene rearrangements: evidence from single-cell polymerase chain reaction examination.
Blood 1995;85(6):1590-5.
1995: Michael Pfreundschuh
['94 oncology update].
Medizinische Klinik (Munich, Germany : 1983) 1995;90(3):144-59.
1994: D Spickermann; Angela Gause; Michael Pfreundschuh; A K Von Kalle; Heribert Bohlen; Volker Diehl
Impaired antibody levels to tetanus toxoid and pneumococcal polysaccharides in acute leukemias.
Leukemia & lymphoma 1994;16(1-2):89-96.
1994: W Jung; S Krueger; C Renner; Angela Gause; Ugur Sahin; L Trümper; Michael Pfreundschuh
Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources.
Molecular immunology 1994;31(17):1329-34.
1994: Lorenz Trümper; B Bürger; F von Bonin; A Hintze; G von Blohn; Michael Pfreundschuh; Heiner Daus
Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions.
British journal of cancer 1994;70(2):278-84.
1994: A Schrauder; Angela Gause; W Jung; Rudolf Mierau; Michael Pfreundschuh
Persistence of a rheumatoid factor (RF)-producing B cell clone with a somatically mutated Ig kappa chain in a patient with rheumatoid arthritis.
Clinical and experimental immunology 1994;97(2):200-3.
1994: J Roth; Heiner Daus; Lorenz Trümper; Angela Gause; M Salamon-Looijen; Michael Pfreundschuh
Detection of immunoglobulin heavy-chain gene rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed-Sternberg cells.
International journal of cancer. Journal international du cancer 1994;57(6):799-804.
1994: R Fuchs; Markus Loeffler; Michael Pfreundschuh; Gottfried Dölken; HH Gerhartz; U Hagen-Aukamp; E Hiller; S Petsch; K H Pflüger; Ursula Rühl
Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
Leukemia & lymphoma 1994;14(1-2):79-89.
1994: C Renner; W Jung; Ugur Sahin; R Denfeld; C Pohl; L Trümper; F Hartmann; Volker Diehl; R van Lier; Michael Pfreundschuh
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Science (New York, N.Y.) 1994;264(5160):833-5.
1994: I Schobert; C Renner; Michael Pfreundschuh; Volker Diehl; C Pohl
Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin's lymphoma.
Leukemia & lymphoma 1994;13(5-6):429-40.
1994: Michael Pfreundschuh; U Rueffer; Bernd Lathan; Norbert Schmitz; O Brosteanu; Dirk Hasenclever; R Haas; H Kirchner; Peter Koch; R Kuse
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):580-6.
1994: J Roth; Heiner Daus; Angela Gause; Lorenz Trümper; Michael Pfreundschuh
Detection of Epstein-Barr virus DNA in Hodgkin- and Reed-Sternberg-cells by single cell PCR.
Leukemia & lymphoma 1994;13(1-2):137-42.
1994: Lorenz Trümper; W Jung; G Dahl; Volker Diehl; Angela Gause; Michael Pfreundschuh
Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():93-6.
1993: Andreas Hombach; W Jung; C Pohl; C Renner; Ugur Sahin; R Schmits; Jürgen Wolf; U Kapp; Volker Diehl; Michael Pfreundschuh
A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
International journal of cancer. Journal international du cancer 1993;55(5):830-6.
1993: Franz-Georg Hanisch; G Heimbüchel; Stephan E Baldus; G Uhlenbruck; R Schmits; Michael Pfreundschuh; M Schwonzen; Mathias Vierbuchen; J Bara; J Peter-Katalinic
Monoclonal antibody FW6 defines an epitope on alpha 3/4-monofucosylated polylactosaminoglycans expressed by fetal and colon carcinoma-associated mucins.
Cancer research 1993;53(18):4367-75.
1993: C Renner; Michael Pfreundschuh; Volker Diehl; C Pohl
Active specific immunotherapy of Hodgkin's lymphoma by an anti-idiotype vaccine against the Hodgkin-associated CD30 antigen.
Annals of the New York Academy of Sciences 1993;690():352-4.
1993: C Pohl; C Renner; M Schwonzen; I Schobert; V Liebenberg; W Jung; Jürgen Wolf; Michael Pfreundschuh; Volker Diehl
CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
International journal of cancer. Journal international du cancer 1993;54(3):418-25.
1993: Bernd Lathan; Michael Pfreundschuh; Volker Diehl
[Therapeutic strategies of Hodgkin's disease].
Der Internist 1993;34(2):146-54.
1992: J Schwamborn; Michael Pfreundschuh
[Update oncology '92. The age of meta-analysis].
Medizinische Klinik (Munich, Germany : 1983) 1992;87(12):646-60.
1992: R Fuchs; Markus Loeffler; Michael Pfreundschuh; Gottfried Dölken; HH Gerhartz; U Hagen-Aukamp; E Hiller; S Petsch; K H Pflüger; Ursula Rühl
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
Medizinische Klinik (Munich, Germany : 1983) 1992;87(11):555-62.
1992: L da Costa; Patrice Carde; Jean Lumbroso; Marcel Ricard; Michael Pfreundschuh; Jacques Bosq; L Manil; Volker Diehl; Claude Parmentier
Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():53-7.
1992: Angela Gause; W Jung; R Schmits; A Tschiersch; R Scholz; C Pohl; Dirk Hasenclever; Volker Diehl; Michael Pfreundschuh
Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():49-52.
1992: Michael Pfreundschuh; Bernd Lathan; Markus Loeffler; U Rüffer; Dirk Hasenclever; Volker Diehl
The Second International Symposium on Hodgkin's Disease. Workshop III: Recommendations for future clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():101-4.
1992: Angela Gause; W Jung; S Keymis; I Schobert; R Scholz; R Schmits; Volker Diehl; C Pohl; Dirk Hasenclever; Michael Pfreundschuh
The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
Leukemia & lymphoma 1992;7(5-6):439-47.
1992: M Schwonzen; Michael Pfreundschuh; C Pohl; A Schuh; Bernd Lathan; V Diehl
Binding of monoclonal anti-interleukin 2 antibody to nucleoli in acute leukemia blast cells.
Leukemia research 1992;16(6-7):589-95.
1992: J Schwamborn; Michael Pfreundschuh
[Stepwise diagnosis of anemia].
Medizinische Klinik (Munich, Germany : 1983) 1992;87(4):188-97.
1992: Angela Gause; S Keymis; R Scholz; I Schobert; W Jung; Volker Diehl; C Pohl; Michael Pfreundschuh
Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.
Lymphokine and cytokine research 1992;11(2):109-13.
1992: M Schwonzen; R Schmits; Stephan E Baldus; Mathias Vierbuchen; Franz-Georg Hanisch; Michael Pfreundschuh; Volker Diehl; J Bara; G Uhlenbruck
Monoclonal antibody FW6 generated against a mucin-carbohydrate of human amniotic fluid recognises a colonic tumour-associated epitope.
British journal of cancer 1992;65(4):559-65.
1992: C Pohl; C Renner; M Schwonzen; M Sieber; P Lorenz; Michael Pfreundschuh; Volker Diehl
Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
International journal of cancer. Journal international du cancer 1992;50(6):958-67.
1992: J Schwamborn; Michael Pfreundschuh
[Oncology update '91].
Medizinische Klinik (Munich, Germany : 1983) 1992;87(1):28-38.
1992: Angela Gause; G Schmitz; A K von Kalle; Bernd Lathan; Volker Diehl; Michael Pfreundschuh
The clinical relevance of IgG subclasses in acute leukemias: low serum IgG as a risk factor for early death due to infection in acute myelogenous leukemia.
Leukemia research 1992;16(2):165-71.
1991: Angela Gause; R Scholz; S Klein; W Jung; Volker Diehl; H Tesch; Dirk Hasenclever; Michael Pfreundschuh
Increased levels of circulating interleukin-6 in patients with Hodgkin's disease.
Hematological oncology 1991;9(6):307-13.
1991: Angela Gause; K Verpoort; V Roschansky; A Tschiersch; Dirk Hasenclever; R Schmits; Volker Diehl; O Brosteanu; Michael Pfreundschuh
The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(8):579-83.
1991: Angela Gause; C Pohl; A Tschiersch; L Da Costa; W Jung; Volker Diehl; Dirk Hasenclever; Michael Pfreundschuh
Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Blood 1991;77(9):1983-8.
1991: C Pohl; M Sieber; Volker Diehl; Michael Pfreundschuh
Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
Anticancer research 1991;11(3):1115-24.
1991: Angela Gause; V Roschansky; A Tschiersch; Kendall A Smith; Dirk Hasenclever; R Schmits; Volker Diehl; Michael Pfreundschuh
Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2 Suppl 2():43-7.
1990: Ugur Sahin; F Hartmann; P Senter; C Pohl; Andreas Engert; Volker Diehl; Michael Pfreundschuh
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
Cancer research 1990;50(21):6944-8.
1990: Angela Gause; Michael Pfreundschuh
[Immunotherapy of malignant diseases using interleukin 2. Bases, results, trends].
Medizinische Klinik (Munich, Germany : 1983) 1990;85(9):561-6, 570.
1990: Wolfgang Hiddemann; Norbert Schmitz; Michael Pfreundschuh; K H Pflüger; J Ollech-Chwoyka; C Tirier; Georg Maschmeyer; H Kirchner; T Wagner; P Koch
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Cancer 1990;66(5):838-43.
1990: Michael Pfreundschuh; C Pohl; C Berenbeck; J Schroeder; W Jung; R Schmits; A Tschiersch; Volker Diehl; Angela Gause
Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis.
International journal of cancer. Journal international du cancer 1990;45(5):869-74.
1990: Patrice Carde; L Da Costa; L Manil; Michael Pfreundschuh; Jean Lumbroso; J C Saccavini; Bernard Caillou; Marcel Ricard; F Boudet; M Hayat
Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines.
European journal of cancer (Oxford, England : 1990) 1990;26(4):474-9.
1990: Volker Diehl; Michael Pfreundschuh; Markus Loeffler; Ursula Rühl; E Hiller; HH Gerhartz; H Kirchner
Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):106-8.
1989: E Schell-Frederick; T Tepass; G Lorscheidt; Michael Pfreundschuh; M Schaadt; Volker Diehl
Effects of recombinant tumor necrosis factor (rHuTNF alpha) on human neutrophils and monocytes: in vitro, ex vivo and in vivo.
European journal of haematology 1989;43(4):286-96.
1989: Michael Pfreundschuh; Patrice Carde; L Da Costa; L Manil; Jean Lumbroso; B Caillou; F Boudet; Marcel Ricard; M Hayat; Volker Diehl
[In vivo imaging of Hodgkin's lymphomas using monoclonal antibodies].
Onkologie 1989;12 Suppl 1():30-3.
1989: Michael Pfreundschuh; B Genth; H Kirchner; P Scheurich; A Lindemann; H T Steinmetz; M Schaadt; Volker Diehl
[Mechanism of resistance to tumor necrosis factor].
Onkologie 1989;12(3):128-30.
1989: M Schaadt; H Burrichter; Michael Pfreundschuh; E Schell-Frederick; Hans Tesch; C Fonatsch; Harald Stein; Volker Diehl
Biology of Hodgkin cell lines.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():53-61.
1989: J O Armitage; M J Barnett; A M Carella; K A Dicke; Volker Diehl; J G Gribben; Michael Pfreundschuh
Bone marrow transplantation in the treatment of Hodgkin's lymphoma: problems, remaining challenges, and future prospects.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():246-53.
1989: Markus Loeffler; Michael Pfreundschuh; Ursula Rühl; E Hiller; HH Gerhartz; R Roloff; M Adler; W Schoppe; U Hagen-Aukamp; G Schmitt
Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():142-62.
1989: M Schwonzen; N Kuehn; B Vetten; V Diehl; Michael Pfreundschuh
Phenotyping of acute myelomonocytic (AMMOL) and monocytic leukemia (AMOL): association of T-cell-related antigens and skin-infiltration in AMOL.
Leukemia research 1989;13(10):893-8.
1989: Patrice Carde; Michael Pfreundschuh; L da Costa; L Manil; Jean Lumbroso; Bernard Caillou; Claude Parmentier; J C Saccavini; Volker Diehl
Radiolabeled monoclonal antibodies against Reed-Sternberg cells for in vivo imaging of Hodgkin's disease by immunoscintigraphy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():101-11.
1989: Volker Diehl; Michael Pfreundschuh; Markus Loeffler; Ursula Rühl; E Hiller; HH Gerhartz; W Wilmanns; H Kirchner; W Schoppe; S Petsch
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Medical oncology and tumor pharmacotherapy 1989;6(2):155-62.
1988: Markus Loeffler; Michael Pfreundschuh; Dirk Hasenclever; E Hiller; HH Gerhartz; W Wilmanns; R Rohloff; Ursula Rühl; G Kühn; R Fuchs
Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group.
Blut 1988;56(6):273-81.
1988: Michael Pfreundschuh; Markus Loeffler; Ursula Rühl; E Hiller; HH Gerhartz; W Wilmanns; H Kirchner; W Schoppe; S Petsch; H Bartels
[Therapy of Hodgkin's lymphomas. Results of the German Hodgkin's Disease Study Group].
Onkologie 1988;11(1):48-52.
1987: Michael Pfreundschuh; W D Schoppe; R Fuchs; K H Pflüger; Markus Loeffler; Volker Diehl
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Cancer treatment reports 1987;71(12):1203-7.
1987: Volker Diehl; Michael Pfreundschuh; Markus Loeffler; K Smith; Ursula Rühl; A Georgii; E Hiller; HH Gerhartz
[Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3].
Onkologie 1987;10(2):62-6.
1986: Volker Diehl; Michael Pfreundschuh; F E Hauser; Markus Loeffler; Ursula Rühl; H Brücher; A Georgii; E Hiller; HH Gerhartz
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group].
Medizinische Klinik (Munich, Germany : 1983) 1986;81(1):1-6.